Lisata Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 54.23 million compared to USD 27.47 million a year ago. Basic loss per share from continuing operations was USD 10.47 compared to USD 7.45 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.648 USD | -0.46% | -1.93% | -3.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.01% | 22M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- LSTA Stock
- News Lisata Therapeutics, Inc.
- Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022